Post Thyroidectomy Myocardial Function
Post Thyroidectomy Myocardial Function
Protocol Synopsis

 Protocol title: Post thyroidectomy myocardial function Purpose: Evaluation of the effects of
 total thyroidectomy on myocardial function Design: Prospective, single-center, cohort study
 Patient Population: Male or female subjects 18 years of age or older who are scheduled for
 total thyroidectomy No. of Subjects: 50 patients, estimated up to 12 months to enroll
 Duration of Treatment: Operation Duration of Follow-up: After discharge, the patients will be
 re-evaluated at three (3), six (6) and twelve (12) months in the outpatient clinic.

 Endpoints: To evaluate the changes in the myocardial function after the removal of the
 thyroid gland.
1.0 INTRODUCTION

 It is commonly known that the thyroid hormones affect the function of the cardiovascular
 system. Several studies mention that these hormones influence the cardiac function and
 geometry directly and indirectly. Three potential mechanisms have been described, which are
 the direct cellular effect, the interaction with the sympathetic nervous system and changes
 in peripheral circulation.

 A few studies have been already published , dealing with the correlation between thyroid
 hormones and heart function. Only one of them have proved a suppressed ventricular
 contractility after subtotal thyroidectomy for hyperthyroidism.

 This clinical trial aims to compare the pre- and post-operative heart function after total
 thyroidectomy, using echocardiography. Outcomes will be assessed during patient
 hospitalization and at three, six and twelve months' follow-up appointments.

 2.0 OBJECTIVES

 To evaluate the effects of total thyroidectomy on the function of the cardiac muscle.

 3.0 DESIGN AND STUDY POPULATION

 The study is designed as a prospective, single-center, cohort study. Any patient that is
 scheduled for a total thyroidectomy will be offered participation in this study if they
 fulfill specific inclusion and exclusion criteria.

 3.3 Duration of the study

 The study will be conducted until at least 50 patients are treated. It is estimated that it
 will take up to 12 months to enroll the patients and an additional 12 months to complete
 follow-up assessments.

 4.0 STUDY PROCEDURE

 4.1 Pre-operative requirements

 Procedures preformed such as routine hospital examinations, antibiotic prophylactic
 treatment, anticoagulant treatment and diet will be according to the standard management
 protocol and will be recorded for the study. The following pre-operative information will be
 recorded:

 1. Demographic information including: name, age, gender, ethnicity

 2. Height, weight, Body Mass Index (B.M.I.) and American Society of Anesthesiologists'
 (A.S.A.) physical status

 3. Behavioral history (Smoking, alcohol or drug use)

 4. Preoperative laboratory findings (Complete blood count, Ca2+, fT3, fT4, TSH, PTH, VitD)

 5. Preoperative echocardiography

 6. Diagnosis including clinical observation and previous imaging results

 7. Medications

 8. Current and past history of surgical and medical comorbidities

 4.3 Pathology data

 The following pathology data will be recorded for all patients:

 1. Post-operative diagnosis including pathology report

 2. Weight of the gland

 3. Dimensions of the gland

 4.4 Postoperative follow-up

 Follow-up evaluation will be performed during hospitalization as well as on the 3rd, 6th and
 12th month after discharge. The following information will be recorded:

 1. Wound condition

 2. Average Pain score for patient resting and moving/day

 3. Postoperative laboratory findings (Complete blood count, Ca2+, fT3, fT4, TSH, PTH, VitD)

 4. Postoperative echocardiography at three (3), six (6) and twelve (12) months.

 5. Clinical signs of hypocalcemia (Chvostek and Trousseau)

 6. Comments

 5.0 COMPLICATIONS AND ADVERSE EVENTS

 The investigators are required to notify the coordinators of any serious adverse events. The
 coordinators are also required to notify the Ethics Committee according to local regulations
 and requirements.

 Serious Adverse Events include:

 1. Death regardless of cause

 2. Any-life-threatening event

 3. Any hospitalization or prolongation of existing hospitalization

 4. Any event that results in persistent or significant disability or incapacity to the
 patient.

 6.0 STATISTICAL ANALYSIS

 The objective of this study is to evaluate the effects of total thyroidectomy on the
 myocardial function.

 Statistical analysis includes description of the pre- and post-operative outcomes, and
 indication of patient characteristics associated with these outcomes.

 Since the study does not have pre-specified hypotheses all statistical analyses are
 exploratory and interpretation of results should be within this context.

 7.0 DATA MONITORING PLAN

 The coordinators will monitor all data. Furthermore, the coordinators will review the
 progress of the clinical trial including safety data and ensure that it is conducted,
 recorded and reported in accordance with the protocol, good clinical practice and the
 applicable regulatory requirements.

 8.0 DATA CONFIDENTIALITY

 Each patient will be identified by his/her initials and a unique patient identification
 number. Source data will be stored with source documents. Only personnel responsible for
 collecting data and transcribing it into the case report forms will have access to the data.
 Records will be protected.

 9.0 FUNDING

 No funding for the execution of the present protocol is considered necessary. The
 investigators are willing to execute the present study without any additional reimbursement.

 10.0 ETHICS

 Prior to the onset of the study, institution review board (IRB) approval should have been
 obtained. Any changes in the study protocol, informed consent forms, or investigator must be
 re-approved by the IRB. All patients enrolled in the study will provide their consent prior
 to entering the study. Informed consent forms shall be signed and dated by the patient. The
 investigator will retain the forms as part of the study records.

 This study will be executed in accordance with the Declaration of Helsinki, in agreement with
 the guidelines for conducting a clinical investigation and the principles of ICH GCP outlined
 in the E6 document. By signing the present protocol, participants in the study commit
 themselves to carry it out with respect to local legal requirements.

 11.0 INFORMED CONSENT

 All eligible patients should have the capacity to provide an written informed consent.

 The above described inclusion and exclusion criteria were designed to ensure the entry of the
 appropriate population of patients to this study and will be approved by the local IRB.
 Screening for these criteria will be conducted by the coordinator.

 Eligible patients will be educated about the research proposal by a study investigator. To
 determine whether the patient has understood the issues, they will be asked to describe what
 the research entails and whether they have any questions. All questions will be addressed
 prior to enrollment. The patient can decline participation in the study at any time.

 A written informed consent form will be generated. For each patient, a case report form (CRF)
 will be completed, providing general medical information and history.
Inclusion Criteria:

 -  Patient is over 18 years old

 -  Patient scheduled for a non-emergency operation

 -  Patient signs and dates a written informed consent form (ICF) and indicates an
 understanding of the study procedures

 -  No previous cardiologic history

 -  Normal PTH values (no transient hypoparathyroidism)

 Exclusion Criteria:

 -  Patient is underage ( under 18 years old)

 -  Patient had a previous operation at the thyroid or parathyroids

 -  Patient inability to participate in follow-up appointments

 -  Patient is participating in another clinical trial which may affect this study's
 outcomes

 -  Patient with TSH values outside the range of normal values

 -  Pathologic Ca2+ , Vit D, P, PTH, pre- and post-operative values

 -  Diabetes Mellitus, Hypertension, History of any heart, lung or systemic disease.